What is the prognosis for a newborn diagnosed with a cavum septum pellucidum (CSP)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 30, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Prognosis of Cavum Septum Pellucidum in Newborns

An isolated cavum septum pellucidum (CSP) in a newborn is a normal anatomical variant with an excellent prognosis and no adverse neurodevelopmental outcomes.

Understanding CSP as a Normal Finding

The cavum septum pellucidum is a fluid-filled space between the two leaves of the septum pellucidum that is universally present during fetal development and commonly persists into infancy:

  • CSP is present in 100% of normal infants below 36 weeks gestational age 1
  • At term, the prevalence decreases: 69% at 36 weeks, 54% at 38 weeks, and 36% at 40 weeks 1
  • The highest incidence (52%) occurs in very preterm infants (<33 weeks) within the first week of life 2
  • After 2 months of age, incidence drops to only 1%, indicating normal developmental closure 2

Prognosis for Isolated CSP

When CSP occurs without other brain abnormalities, the prognosis is uniformly favorable:

  • All cases with isolated abnormal CSP width (narrow or wide) followed prenatally demonstrated normal neurodevelopment 3
  • Children with isolated CSP diagnosed postnatally show no differences in neurocognitive ability, motor function, or behavior compared to children without CSP 4
  • In one study, 58% of children with CSP had normal mental development, and mental retardation occurred in only 11% of children with isolated CSP 5

When CSP Indicates Concern

The critical distinction is whether CSP occurs in isolation or with associated brain malformations:

  • In 67% of cases, CSP coexists with other structural brain abnormalities 5
  • When associated with other malformations (dysplasia septo-optica, corpus callosum agenesis), 35% of children had mental retardation 5
  • CSP associated with major brain malformations is typically diagnosed earlier (average age 5 years) compared to isolated CSP (average age 10 years) 5
  • Absence of septum pellucidum (not CSP) is a midline anomaly that can be associated with PHACE syndrome and requires evaluation 4

Clinical Management Approach

For isolated CSP detected in a newborn:

  • No additional evaluation, follow-up imaging, or postnatal assessment is indicated 4
  • Reassure parents that this is a normal variant of no clinical importance 4
  • Standard developmental surveillance per American Academy of Pediatrics guidelines is sufficient 4

If CSP is associated with other findings:

  • Comprehensive brain MRI to identify coexisting structural abnormalities 5
  • Evaluate for specific syndromes if multiple anomalies present (PHACE syndrome if facial hemangiomas, cardiovascular anomalies) 4
  • Formal developmental assessment and ongoing monitoring if associated malformations are identified 5

Important Caveats

  • Normal CSP dimensions: Width should be <0.95 cm and depth <0.81 cm; measurements exceeding these may represent anomalous midline development 1
  • Ultrasound may incorrectly diagnose "absent CSP" when a narrow CSP is actually present; MRI should be offered when absence is suspected on ultrasound 3
  • The size of CSP (width, depth, area) does not change significantly with age, birth weight, or biparietal diameter 1
  • Cleft-shaped CSP is associated with severe traumatic brain injury but is not relevant to newborns without trauma history 6

References

Research

Prenatal abnormal width of the cavum septum pellucidum - MRI features and neurodevelopmental outcome.

The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians, 2018

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.